US 12,030,889 B2
Imidazopyridazine and imidazopyridine compounds and uses thereof
Jun Pan, Media, PA (US); Jeremy Roach, Philadelphia, PA (US); Song Mei, Wilmington, DE (US); Chunhong He, Boothwyn, PA (US); Liangxing Wu, Wilmington, DE (US); and Wenqing Yao, Chadds Ford, PA (US)
Assigned to Incyte Corporation, Wilmington, DE (US)
Filed by Incyte Corporation, Wilmington, DE (US)
Filed on Jun. 9, 2022, as Appl. No. 17/836,602.
Application 17/836,602 is a continuation of application No. 16/720,935, filed on Dec. 19, 2019, granted, now 11,459,329.
Claims priority of provisional application 62/935,891, filed on Nov. 15, 2019.
Claims priority of provisional application 62/782,994, filed on Dec. 20, 2018.
Prior Publication US 2022/0315595 A1, Oct. 6, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 487/04 (2006.01); C07D 519/00 (2006.01); A61K 31/519 (2006.01)
CPC C07D 487/04 (2013.01) [C07D 519/00 (2013.01); A61K 31/519 (2013.01)] 12 Claims
 
1. A compound which is 5-(7-(1-Isopropyl-1H-pyrazol-4-yl)-6-methylimidazo[1,2-b]pyridazin-3-yl)-2-(pyrimidin-2-yl)-1,8-naphthyridine.